Comparative Pharmacology
Head-to-head clinical analysis: REDEMPLO versus TRYNGOLZA AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REDEMPLO versus TRYNGOLZA AUTOINJECTOR.
REDEMPLO vs TRYNGOLZA (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
REDEMPLO is a synthetic tricyclic analog that acts as a selective serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It binds to the presynaptic transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT), inhibiting their reuptake and increasing synaptic concentrations of these monoamines. Additionally, it has weak antagonistic properties at the 5-HT2A and alpha-2 adrenergic receptors, contributing to its antidepressant and anxiolytic effects.
Selective inhibitor of protein kinase C theta (PKCθ), reducing T cell activation and cytokine production.
100 mg orally once daily, with or without food.
0.5 mg subcutaneously once daily.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and end-stage renal disease (up to 40 hours).
Terminal elimination half-life is approximately 21 days (range 14–28 days), consistent with slow clearance from plasma due to target-mediated drug disposition.
Primarily hepatic metabolism with 70% renal excretion of metabolites and 30% fecal elimination; less than 5% excreted unchanged in urine.
Primarily eliminated via the reticuloendothelial system; no significant renal or biliary excretion. <1% excreted unchanged in urine.
Category C
Category C
Unknown
Unknown